About Forus
Leadership
Values
Latest News
WELCOME, Marie-Eve Caron
FORUS Therapeutics is thrilled to announce Marie-Eve Caron as Associate Director, Sales. Marie-Eve brings more than 20 years of pharmaceutical experience, including over 13 years in specialty care across immunology and hematology/oncology. Throughout her career, she...
FORUS Therapeutics Inc Announces Health Canada Approval of BESREMI® (ropeginterferon alfa-2b) for Polycythemia Vera (PV)
(OAKVILLE, Ontario) July 6, 2026 – FORUS Therapeutics Inc (“FORUS”), a wholly owned subsidiary of PharmaEssentia Corp, is pleased to announce that it has received a Notice of Compliance (NOC) authorizing BESREMI® (ropeginterferon alfa-2b) for the treatment of adults...
FORUS Therapeutics Joins PharmaEssentia to Strengthen Focus on Hematology and Oncology in Canada
(OAKVILLE, Ontario) June 11, 2026 – FORUS Therapeutics Inc (“FORUS”) is pleased to announce that it has been acquired by PharmaEssentia Corporation, a global biopharmaceutical company focused on developing innovative therapies for hematology, oncology, and...
Contact Us
Mailing Address:
FORUS Therapeutics Inc.
200 North Service Road West, Suite 129
Oakville, Ontario, L6M 2Y1
Phone: 1-877-359-9595
Fax: 1-877-359-9590
Patient Support:
Phone: 1-833-4YOUPSP (1-833-496-8777)
Fax: 1-833-4YOUFAX (1-833-496-8329)
Product Support:
Phone: 1-866-542-7500
Fax: 1-866-542-1100
Do not use this form to report adverse events. Adverse events can be reported at 1-866-542-7500.
